wolters kluwer medi-span generic product identifier (gpi) codes (Wolters Kluwer Health)
90
Structured Review
Wolters Kluwer Health
wolters kluwer medi-span generic product identifier (gpi) codes
Wolters Kluwer Medi Span Generic Product Identifier (Gpi) Codes, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/medi-span+generic+product+identifier+(gpi)/medi+span+generic+product+identifier++gpi+/pm39240484-23-6-4
Average 90 stars, based on 1 article reviews
Wolters Kluwer Medi Span Generic Product Identifier (Gpi) Codes, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/medi-span+generic+product+identifier+(gpi)/medi+span+generic+product+identifier++gpi+/pm39240484-23-6-4
Average 90 stars, based on 1 article reviews
wolters kluwer medi-span generic product identifier (gpi) codes - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Biomarker Discovery:Article Title: Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation. Article Snippet: Antipsychotic medication is the mainstay of pharmacological treatment for schizophrenia, prescribed for both acute episodes and maintenance therapy (Keepers et al., 2020).. While these drugs have demonstrated effectiveness in managing schizophrenia symptoms, they are also associated with serious extrapyramidal symptoms (EPS), including acute dystonia, akathisia, and parkinsonism, as well as with tardive dyskinesia (TD) (Crawford & Go, 2022; Divac et al., 2014; Haddad et al., 2012; Schultz et al., 2007).. Caroff et al. provide detailed descriptions of these involuntary movement symptoms, which are often distressing, burdensome, Kristin Richards krichards@austin.utexas.edu Article Title: Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. Article Snippet: Medications were identified by Article Title: A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies. Article Snippet: Products were defined by the Article Title: Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Article Snippet: The purpose of this study is to investigate 1-year adherence rates to aromatase inhibitors (AI) and to determine risk factors for non-adherence among commercially insured post-menopausal breast cancer patients.. A retrospective cohort of 13,593 commercially insured breast cancer patients with a prescription claim for an AI therapy (exemestane, anastrozole, and letrozole) in 2006 were identified using the MarketScan Commercial Claims and Encounters Database.. Adherence was calculated by the medication possession ratio (MPR) for a 1-year period following the initial claim in 2006. Modification:Article Title: Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation. Article Snippet: Antipsychotic medication is the mainstay of pharmacological treatment for schizophrenia, prescribed for both acute episodes and maintenance therapy (Keepers et al., 2020).. While these drugs have demonstrated effectiveness in managing schizophrenia symptoms, they are also associated with serious extrapyramidal symptoms (EPS), including acute dystonia, akathisia, and parkinsonism, as well as with tardive dyskinesia (TD) (Crawford & Go, 2022; Divac et al., 2014; Haddad et al., 2012; Schultz et al., 2007).. Caroff et al. provide detailed descriptions of these involuntary movement symptoms, which are often distressing, burdensome, Kristin Richards krichards@austin.utexas.edu Article Title: Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. Article Snippet: Medications were identified by Article Title: A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies. Article Snippet: Products were defined by the Article Title: Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Article Snippet: The purpose of this study is to investigate 1-year adherence rates to aromatase inhibitors (AI) and to determine risk factors for non-adherence among commercially insured post-menopausal breast cancer patients.. A retrospective cohort of 13,593 commercially insured breast cancer patients with a prescription claim for an AI therapy (exemestane, anastrozole, and letrozole) in 2006 were identified using the MarketScan Commercial Claims and Encounters Database.. Adherence was calculated by the medication possession ratio (MPR) for a 1-year period following the initial claim in 2006. |